Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

Start-up raises more funds for AI-designed macrocycles

by Rowan Walrath
June 13, 2024 | A version of this story appeared in Volume 102, Issue 18

 

Nearly 2 years after launching from David Baker’s lab at the University of Washington’s Institute for Protein Design, Vilya Therapeutics expanded its series A financing round by $21 million, to $71 million raised. Vilya has so far used its computational platform to identify macrocyclic peptides that can bind to multiple proteins (Science 2024, DOI: 10.1126/science.adk1687). The new investment, whose funders include Arch Venture Partners and the venture arm of the tech company Nvidia, will be used to ready these peptides for testing in humans, Vilya says.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.